ACRV

Acrivon Therapeutics, Inc.

2.13 USD

Last updated Sep 4, 21:00 UTC

Yesterday HIGH

$2.15

Yesterday LOW

$2.05

52w HIGH

$3.55

52w LOW

$1.27

EPS

-0.43

PE

-4.95

Next Earnings

Nov 12, 2026

Overview News Insider Transactions Government Trades Fundamentals

Acrivon Therapeutics, Inc. stock is up 29.88% since 30 days ago. The next earnings date is Nov 12, 2026. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 3 September’s closed higher than August.

Benzinga Newsdesk

Wed Aug 12, 2026

Acrivon Therapeutics Q2 EPS $(0.43) Beats $(0.50) Estimate

Acrivon Therapeutics (NASDAQ:ACRV) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.50) by 14 percent. This is a 21.82 percent increase over losses of $(0.55) per share
Benzinga Newsdesk

Wed Aug 5, 2026

Acrivon Therapeutics Says ACR-2316 Advances Into Randomized Dose Expansion Portion Of Its Ongoing Phase 1/2 Study

Favorable, differentiated safety profile and durable single-agent clinical activity, including in heavily pretreated subjects with lung cancer remaining on treatment for over a yearOral weekly regimen (3 days on/4 days
Benzinga Newsdesk

Tue Jul 21, 2026

Acrivon Therapeutics To Highlight AP3 Platform For Pathway-Based Drug Discovery And Development At AACR D3 July 21-24

Presentations and DetailsOral Podium PresentationTitle: Acrivon Predictive Precision Proteomics (AP3): Next Generation Precision Medicine for Phosphoproteomics-Guided Drug DiscoveryPresenter: Lei Shi, Ph.D., Director
Benzinga Newsdesk

Wed May 13, 2026

Acrivon Therapeutics Q1 EPS $(0.49) Beats $(0.53) Estimate

Acrivon Therapeutics (NASDAQ:ACRV) reported quarterly losses of $(0.49) per share which beat the analyst consensus estimate of $(0.53) by 7.55 percent. This is a 3.92 percent increase over losses of $(0.51) per share
Benzinga Newsdesk

Fri Apr 17, 2026

Acrivon Therapeutics Presents Preclinical Data On Three Posters At AACR 2026

Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics

Michaela Levin, Chief Business Officer

Mon Aug 31, 2026

ACRV Recent Insider Trades and Stock Chart

130,000 shares awarded
Michaela Levin, Chief Business Officer

Mon Aug 31, 2026

ACRV Recent Insider Trades and Stock Chart

30,000 shares awarded
Peter BlumeJensen, President and CEO

Tue Aug 25, 2026

ACRV Recent Insider Trades and Stock Chart

14,036 shares sold
Katharine Peterson, Chief Accounting Officer

Tue Aug 18, 2026

ACRV Recent Insider Trades and Stock Chart

101 shares sold
Mary Miller, Chief Legal Officer

Tue Aug 18, 2026

ACRV Recent Insider Trades and Stock Chart

185 shares sold
Erick Gamelin, Chief Development Officer

Tue Aug 18, 2026

ACRV Recent Insider Trades and Stock Chart

400 shares sold
Eric Devroe, Chief Operating Officer

Tue Aug 18, 2026

ACRV Recent Insider Trades and Stock Chart

604 shares sold
Peter BlumeJensen, President and CEO

Tue Aug 18, 2026

ACRV Recent Insider Trades and Stock Chart

1,713 shares sold
Adam D Levy, Chief Financial Officer

Tue Aug 4, 2026

ACRV Recent Insider Trades and Stock Chart

1,142 shares sold